Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study
Journal of Parenteral and Enteral Nutrition · 2025
DOI: 10.1002/jpen.2786 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Parenteral and Enteral Nutrition, 2025. Verfasst von Elizabeth S L Low und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Gastrointestinal Agents, Intestinal Failure, Peptides. Die Arbeit nennt 24 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Background
International evidence supports the efficacy of teduglutide in reducing parenteral support requirements, or achieving enteral autonomy, in patients with short bowel syndrome–intestinal failure. This is a multicenter observational study presenting the real‐world experience with teduglutide in Australia. Materials and Methods 11 of 12 Australian intestinal rehabilitation units submitted data for 19 adult patients with short bowel syndrome–intestinal failure prescribed teduglutide from November 2020 to August 2023. Patient and clinical characteristics, including teduglutide dosing and parenteral support prescriptions, were collected at 3‐month intervals for 12 months from teduglutide initiation and finally at study termination. Univariate analysis was conducted and results presented as medians with interquartile ranges (IQRs).
Results
Seventy‐four percent of the cohort (median age 58 [IQR 44–67] years) were female. The median residual small bowel length was 85 cm (IQR 60–118), with 53% having colon in continuity. Prior to teduglutide commencement, median parenteral support duration was 3.8 (IQR 1.1–11.0) years, with weekly parenteral support volumes of 11.5 (IQR 6.2–15.3) L/week. Seven patients (37%) achieved enteral autonomy, with five weaned off by 12 months and the remaining between 12–42 months from teduglutide initiation. 79% achieved ≥20% parenteral support volume reductions, with overall median parenteral support volume reductions of 28% after 12 months. Baseline quality‐of‐life assessments suggested that sexual function, travel ability, and sleep patterns were areas of greatest disease burden.
Conclusion
Within an Australian cohort, teduglutide is effective at reducing parenteral support requirements in patients with short bowel syndrome–intestinal failure, although the effect onset and range remains heterogenous.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.
- Australian Centre for Transplantation Excellence and Research, Melbourne, VIC, Australia.
- Department of Surgery (Austin Precinct), University of Melbourne, Melbourne, VIC, Australia.
- Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
ORCID-Profile: Elizabeth S L Low, Brooke Chapman, Darren Wong
Förderung
- None
Zitieren
APA
Low, E. S. L., Burrell, K., Tan, K., Chapman, B., Testro, A., & Wong, D. (2025). Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study. Journal of Parenteral and Enteral Nutrition. https://doi.org/10.1002/jpen.2786
Vancouver
Low ESL, Burrell K, Tan K, Chapman B, Testro A, Wong D. Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study. Journal of Parenteral and Enteral Nutrition. 2025. doi:10.1002/jpen.2786
BibTeX
@article{Low2025,
author = {Low, Elizabeth S L and Burrell, Kathryn and Tan, Katrina and Chapman, Brooke and Testro, Adam and Wong, Darren},
title = {Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study},
journal = {Journal of Parenteral and Enteral Nutrition},
year = {2025},
doi = {10.1002/jpen.2786}
}
EUVIMED